Expression analysis following argon treatment in an in vivo model of transient middle cerebral artery occlusion in rats

Medical Gas Research

Volumn 4, Issue 1, 2014, Pages

  Fahlenkamp, Astrid V ^a   Coburn, Mark ^a   De Prada, Antonio ^a   Gereitzig, Nadine ^a   Beyer, Cordian ^c   Haase, Hajo ^a   Rossaint, Rolf ^a   Gempt, Jens ^b   Ryang, Yu Mi ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Argon; Ischemia; MCAO; Neuroprotection; Noble gas

Indexed keywords

ARGON; CALCIUM BINDING PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; IONIZED CALCIUM BINDING ADAPTOR MOLECULE 1; NERVE GROWTH FACTOR; NEURON SPECIFIC NUCLEAR PROTEIN; PLACEBO; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN ISCHEMIA; CELL COUNT; CONTROLLED STUDY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INDUCIBLE NITRIC OXIDE SYNTHASE GENE; INTERLEUKIN 1BETA GENE; INTERLEUKIN 6 GENE; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE CELL; NERVE GROWTH FACTOR GENE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA GENE;

EID: 84907873393     PISSN: None     EISSN: 20459912     Source Type: Journal    
DOI: 10.1186/2045-9912-4-11     Document Type: Article

References (34)

1. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H, American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology: Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013, 44:870-947.
2. The European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee: Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008. Cerebrovasc Dis 2008, 25:457-507.
3. Bandera E, Botteri M, Minelli C, Sutton A, Abrams KR, Latronico N: Cerebral blood flow threshold of ischemic penumbra and infarct core in acute ischemic stroke: a systematic review. Stroke 2006, 37:1334-1339.
4. Dickinson R, Franks NP: Bench-to-bedside review: Molecular pharmacology and clinical use of inert gases in anesthesia and neuroprotection. Crit Care 2010, 14:229.
5. Sheng SP, Lei B, James ML, Lascola CD, Venkatraman TN, Jung JY, Maze M, Franks NP, Pearlstein RD, Sheng H, Warner DS: Xenon neuroprotection in experimental stroke: interactions with hypothermia and intracerebral hemorrhage. Anesthesiology 2012, 117:1262-1275.
6. Brücken A, Cizen A, Fera C, Meinhardt A, Weis J, Nolte K, Rossaint R, Pufe T, Marx G, Fries M: Argon reduces neurohistopathological damage and preserves functional recovery after cardiac arrest in rats. Br J Anaesth 2013, 110(Suppl 1):i106-i112.
7. Zhuang L, Yang T, Zhao H, Fidalgo AR, Vizcaychipi MP, Sanders RD, Yu B, Takata M, Johnson MR, Ma D: The protective profile of argon, helium, and xenon in a model of neonatal asphyxia in rats. Crit Care Med 2012, 40:1724-1730.
8. David HN, Haelewyn B, Degoulet M, Colomb DG Jr, Risso JJ, Abraini JH: Ex vivo and in vivo neuroprotection induced by argon when given after an excitotoxic or ischemic insult. PLoS One 2012, 7:e30934.
9. Harris K, Armstrong SP, Campos-Pires R, Kiru L, Franks NP, Dickinson R: Neuroprotection against traumatic brain injury by xenon, but not argon, is mediated by inhibition at the N-methyl-D-aspartate receptor glycine site. Anesthesiology 2013, 119:1137-1148.
10. Ryang YM, Fahlenkamp AV, Rossaint R, Wesp D, Loetscher PD, Beyer C, Coburn M: Neuroprotective effects of argon in an in vivo model of transient middle cerebral artery occlusion in rats. Crit Care Med 2011, 39:1448-1453.
11. Behnke AR, Yarbrough OD: Respiratory resistance, oil-water solubility, and mental effects of argon, compared with helium and nitrogen. Am J Physiol 1939, 126:409-415.
12. Fahlenkamp AV, Rossaint R, Haase H, Al Kassam H, Ryang YM, Beyer C, Coburn M: The noble gas argon modifies extracellular signal-regulated kinase 1/2 signaling in neurons and glial cells. Eur J Pharmacol 2012, 674:104-111.
13. Koizumi J, Yoshida Y, Nakazawa T, Ooneda G: Experimental studies of ischemic brain edema: I: A new experimental model of cerebral embolism in which recirculation can be introduced into the ischemic area. Jpn J Stroke 1986, 8:1-8.
14. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H: Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986, 17:472-476.
15. Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL, Bartkowski HM: Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 1986, 17:1304-1308.
16. Kramer M, Dang J, Baertling F, Denecke B, Clarner T, Kirsch C, Beyer C, Kipp M: TTC staining of damaged brain areas after MCA occlusion in the rat does not constrict quantitative gene and protein analyses. J Neurosci Methods 2010, 187:84-89.
17. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR: A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 1990, 10:290-293.
18. Rizvi M, Jawad N, Li Y, Vizcaychipi MP, Maze M, Ma D: Effect of noble gases on oxygen and glucose deprived injury in human tubular kidney cells. Exp Biol Med (Maywood) 2010, 235:886-891.
19. Loetscher PD, Rossaint J, Rossaint R, Weis J, Fries M, Fahlenkamp A, Ryang YM, Grottke O, Coburn M: Argon: neuroprotection in in vitro models of cerebral ischemia and traumatic brain injury. Crit Care 2009, 13:R206.
20. Huang J, Upadhyay UM, Tamargo RJ: Inflammation in stroke and focal cerebral ischemia. Surg Neurol 2006, 66:232-245.
21. Denes A, Pinteaux E, Rothwell NJ, Allan SM: Interleukin-1 and stroke: biomarker, harbinger of damage, and therapeutic target. Cerebrovasc Dis 2011, 32:517-527.
22. Tarkowski E, Rosengren L, Blomstrand C, Wikkelso C, Jensen C, Ekholm S, Tarkowski A: Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 1995, 26:1393-1398.
23. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW: Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994, 83:113-118.
24. Ali C, Nicole O, Docagne F, Lesne S, MacKenzie ET, Nouvelot A, Buisson A, Vivien D: Ischemia-induced interleukin-6 as a potential endogenous neuroprotective cytokine against NMDA receptor-mediated excitotoxicity in the brain. J Cereb Blood Flow Metab 2000, 20:956-966.
25. Wang X, Yue TL, Young PR, Barone FC, Feuerstein GZ: Expression of interleukin-6, c-fos, and zif268 mRNAs in rat ischemic cortex. J Cereb Blood Flow Metab 1995, 15:166-171.
26. Wang X, Yue TL, Barone FC, White RF, Gagnon RC, Feuerstein GZ: Concomitant cortical expression of TNF-alpha and IL-1 beta mRNAs follows early response gene expression in transient focal ischemia. Mol Chem Neuropathol 1994, 23:103-114.
27. Prüss H, Prass K, Ghaeni L, Milosevic M, Muselmann C, Freyer D, Royl G, Reuter U, Baeva N, Dirnagl U, Meisel A, Priller J: Inducible nitric oxide synthase does not mediate brain damage after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab 2008, 28:526-539.
28. Kidd GA, Hong H, Majid A, Kaufman DI, Chen AF: Inhibition of brain GTP cyclohydrolase I and tetrahydrobiopterin attenuates cerebral infarction via reducing inducible NO synthase and peroxynitrite in ischemic stroke. Stroke 2005, 36:2705-2711.
29. Ruocco A, Nicole O, Docagne F, Ali C, Chazalviel L, Komesli S, Yablonsky F, Roussel S, MacKenzie ET, Vivien D, Hbuissob A: A transforming growth factor-beta antagonist unmasks the neuroprotective role of this endogenous cytokine in excitoxic and ischemic brain injury. J Cereb Blood Flow Metab 1999, 19:1345-1353.
30. Dhandapani KM, Brann DW: Transforming growth factor-beta: a neuroprotective factor in cerebral ischemia. Cell Biochem Biophys 2003, 39:13-22.
31. Yang JP, Liu HJ, Yang H, Feng PY: Therapeutic time window for the neuroprotective effects of NGF when administered after focal cerebral ischemia. Neurol Sci 2011, 32:433-441.
32. Yang J, Guo L, Liu R, Liu H: Neuroprotective effects of VEGF administration after focal cerebral ischemia/reperfusion: dose response and time window. Neurochem Int 2012, 60:592-596.
33. Limatola V, Ward P, Cattano D, Gu J, Giunta F, Maze M, Ma D: Xenon preconditioning confers neuroprotection regardless of gender in a mouse model of transient middle cerebral artery occlusion. Neuroscience 2010, 165:874-881.
34. Zhao H, Watts HR, Chong M, Huang H, Tralau-Stewart C, Maxwell PH, Maze M, George AJ, Ma D: Xenon treatment protects against cold ischemia associated delayed graft function and prolongs graft survival in rats. Am J Transplant 2013, 13:2006-2018.